Precision medicine: Lessons learned from the SHIVA trial

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages e579-e580

  Tsimberidou, Apostolia M ^a   Kurzrock, Razelle ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EVEROLIMUS; IMATINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADVANCED CANCER; BRAF GENE; BREAST CANCER; CANCER SURVIVAL; COMORBIDITY; GENE MUTATION; HORMONAL THERAPY; HUMAN; IC50; LETTER; META ANALYSIS (TOPIC); NEOPLASM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; GENE EXPRESSION PROFILING; GENETICS; MALE; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE;

EID: 84961662117     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00397-6     Document Type: Letter

References (11)

1. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015, 16:1324-1334.
2. Janku F, Hong DS, Fu S, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014, 6:377-387.
3. Prat A, Baselga J The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 2008, 5:531-542.
4. Skinner MA, Safford SD, Freemerman AJ RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 2003, 23:3601-3606.
5. Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010, 28:4877-4883.
6. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012, 18:6373-6383.
7. Jameson GS, Petricoin EF, Sachdev J, et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat 2014, 147:579-588.
8. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006.
9. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015, 373:726-736.
10. Schwaederle M, Zhao M, Lee JJ, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol 2015, 33:3817-3825.
11. Fontes Jardim DL, Schwaederle M, Wei C, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst 2015, 107:djv253.